These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28702244)

  • 1. Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.
    Portillo-Sanchez P; Cusi K
    Clin Diabetes Endocrinol; 2016; 2():9. PubMed ID: 28702244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological management of nonalcoholic fatty liver disease.
    Barb D; Portillo-Sanchez P; Cusi K
    Metabolism; 2016 Aug; 65(8):1183-95. PubMed ID: 27301803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.
    Kothari S; Dhami-Shah H; Shah SR
    J Clin Exp Hepatol; 2019; 9(6):723-730. PubMed ID: 31889754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 10. GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients.
    Adeghate EA
    Expert Opin Pharmacother; 2024 Feb; 25(3):223-232. PubMed ID: 38458647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
    Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis.
    Sumida Y; Yoneda M; Tokushige K; Kawanaka M; Fujii H; Yoneda M; Imajo K; Takahashi H; Eguchi Y; Ono M; Nozaki Y; Hyogo H; Koseki M; Yoshida Y; Kawaguchi T; Kamada Y; Okanoue T; Nakajima A; Jsg-Nafld JSGON
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
    Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T
    Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).
    Lomonaco R; Chen J; Cusi K
    Ther Adv Endocrinol Metab; 2011 Oct; 2(5):211-25. PubMed ID: 23148186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review.
    Kaur S; Sojitra V; Zahra A; Hutchinson J; Folawemi O; Bittla P; Ramphall S
    Cureus; 2023 Sep; 15(9):e45789. PubMed ID: 37745748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
    Stein LL; Dong MH; Loomba R
    Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
    Dhir G; Cusi K
    J Investig Med; 2018 Jan; 66(1):7-10. PubMed ID: 28918389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study.
    Miyake T; Yoshida O; Matsuura B; Furukawa S; Hirooka M; Abe M; Tokumoto Y; Koizumi Y; Watanabe T; Takeshita E; Sunago K; Yukimoto A; Watanabe K; Miyazaki M; Kanzaki S; Nakaguchi H; Koizumu M; Yamamoto Y; Kumagi T; Hiasa Y
    Diabetes Ther; 2022 May; 13(5):1083-1096. PubMed ID: 35312970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.